AUCTORES
Globalize your Research
Mini-Review
*Corresponding Author: Muhammad Shariq Mukarram, Department of Internal Medicine, Jinnah Medical College Hospital, Karachi, Pakistan.
Citation: Muhammad I Ghauri, Muhammad S Mukarram, Jibran S Muhammad. (2020) Debate on the Effectiveness of Hydroxychloroquine for Treatment of Coronavirus Disease 2019 (COVID-19). Biomedical Research and Clinical Reviews. 1(5); DOI:10.31579/2692-9406/028
Copyright: © 2020 Muhammad Shariq Mukarram, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 18 October 2020 | Accepted: 14 November 2020 | Published: 18 November 2020
Keywords: sars-cov-2; covid-19; hydroxychloroquine; rheumatic diseases
The recent outbreak of Coronavirus disease (COVID-19) caused by novel SARS-CoV-2 has raised global health concerns putting many lives at stake. Such condition calls for an urgent demand for effective, available and affordable drugs to control the viral illness. Several different therapies are under study and no definite treatment has yet been approved. Hydroxychloroquine, an antimalarial agent with immunomodulatory and anti-viral properties, remains the hot topic of discussion. The drug has demonstrated potent in vitro activity against SARS-CoV-2. This article presents a review of published literature from the year 2020 (Jan-Apr). This aimed article aimed to review the effectiveness of Hydroxychloroquine in treating patients with COVID-19. Based on the available literature, we recommend the use of this agent in treating patients with active SARS-CoV-2 infection.
The first case of the Coronavirus was reported in Wuhan, the largest metropolitan city in China’s Hubei province on 30th December 2019. Prompt measures were taken by the Centre for Disease Control and Prevention (CDC) and the Chinese health authorities. This illness was temporarily named as the 2019 novel Corona-virus (2019-nCOV) by the World Health Organization (WHO). After the release of the first whole-genome sequence on the 10th of January 2020, researchers were quickly able to identify the viral illness in patients using reverse-transcriptase polymerase chain reaction (RT-PCR). Before this, the initial cases were classified as “Pneumonia of unknown origin”. Researchers found that this virus belongs to the beta coronavirus group, similar to SARS Coronaviruse. On February 12th 2020, the WHO named this pathogen as SARS-CoV-2 and the disease caused by it as Coronavirus disease 2019 (COVID 2019). Unfortunately, on 11th March 2020, COVID -19 was recognized by WHO as a pandemic spreading to over 150 countries [1-2].
We used the MeSH terms “Pandemic”, SARS-CoV-2” and “COVID-19” with “Hydroxychloroquine” and “rheumatic diseases” to search the scientific databases such as SCOPUS, PubMed and Google Scholar. A total of 12 studies were included in the review.
Structure of Coronavirus
Coronaviruses are single-stranded RNA viruses. SARS-CoV-2 is classified under the beta Coronaviruses group. The genetic framework of the virus consists of a 5’-untranslated region (UTR), a replicase complex encoding non-structural proteins (NSPS), a spike protein (S) gene, an envelope protein (E) gene, a membrane protein (M) gene, neucleocapsid protein (N) gene, 3’-UTR and multiple unidentified non-structural open-reading frames (figure 1a). Owing to the presence of its spike glycoprotein on the envelope, it has a crown-like appearance on electron microscopy [1-3].
Transmission
Human to human transmission of the virus has well been established with the symptomatic population being the most frequent source of the spread. The possibility of transmission of the disease before the development of symptoms seems to be infrequent. The incubation period varies between 3 to 7 days and may prolong up to 2 weeks. Data from the first cases from Wuhan and investigations conducted by CDC china showed that the viral illness doubled every 7 days, whereas the basic reproduction number is 2.2. Close contact is necessary for the spread of SARS-CoV-2 and therefore, family members and health care workers are at higher risk. This is why; the use of isolation has been suggested as the best way to contain the ailment [2].
Besides that, SARS CoV-2 can also infect the human gastrointestinal tract, therefore fecal-oral spread is likely to occur from the viral disease [4].
Clinical features and diagnosis
Common clinical features of COVID-19 include fever (80-90%) along with respiratory symptoms; dry cough (48-76%) and shortness and breath (30-55%). Other frequent characteristics include loss of appetite, productive cough, less commonly headache, diarrhea, nausea and vomiting [4].
Clinical diagnosis is based on symptomatology and exposure history, along with chest image findings. Definite diagnosis requires the detection of the virus using the PCR technique. The virus can be found in the upper respiratory tract in nearly all patients therefore, nasopharyngeal and oropharyngeal swabs are preferred samples [4].
Treatment options
Searching for effective therapies for COVID-19 infection is a complex process. No drugs have been approved for the prevention or treatment of COVID-19. Numerous agents are being investigated as potential therapies. Amongst these, few are those that were previously used to treat SARS and MERS outbreak [5-6].
Chloroquine and Hydroxychloroquine:
These agents have a long-standing history in the treatment and prophylaxis of malaria and the treatment of chronic rheumatic diseases [7]. Chloroquine and hydroxychloroquine block the entry of the virus into cells by inhibiting glycosylation of host receptors and endosomal acidification, as discussed in detail ahead [8-9].
Lopinavir/Ritonavir:
This is an oral combination, approved by the US food and drug administration, used to treat HIV infection. It has demonstrated in vitro activity against other novel coronaviruses through inhibition of 3-chymotrypsin like protease [10-11]. However, no published data exists for Lopinavir/Ritonavir with in vitro activity against SARS-CoV-2 [12].
Ribavirin:
Ribavirin is a guanine analog that inhibits viral RNA-dependent polymerase. It is also active against other novel coronaviruses. Itsin vitro activity against SARS-CoV-2 is very limited and required very high doses (1.2-2.4g every 8 hours) to inhibit the viral replication. Adverse effects including hematologic and hepatotoxicity were common [5].
Oseltamivir:
Oseltamivir is a neuraminidase inhibitor approved for treatment in Influenza. Unfortunately, this agent has no documented in vitro activity against SARS-CoV-2 [13].
Umifenovir:
This anti-viral agent targets the S protein/ACE2 interaction and inhibits the membrane fusion of the viral envelope. This unique mechanism of action makes it a promising drug for the treatment of COVID-19 and is currently under different trials [14].
Remdesivir:
Remdesivir is a monophosphate pro-drug that undergoes metabolism to C-adenosine triphosphate, an active analog. Due to its low EC50 and host polymerase selectivity against the Ebola virus, the first clinical use of Remdesivir was for Ebola during the Ebola virus outbreak [15-16]. Owing to its broad spectrum and potent in vitro activity against several novel coronaviruses including SARS-CoV-2, this agent is a promising potential therapy for COVID-19 [17-18]. Successful case reports have been reported, describing the use of Remdesivir in the treatment of COVID-19 [19-20].
Molecule and uses of Hydroxychloroquine
Hydroxychloroquine is a derivative of Chloroquine and is a 4-aminoquinoline with three distinct properties: immunosuppressive, anti-autophagy, and anti-malarial activities. This drug suppresses the immune system by interfering with the processing and presentations of antigens and cytokine production. It also raises the pH within the lysosome, impairing the autophagic degradation of the protein. It alters the assembly of macromolecules in the endosomes and post-translation modification of proteins in the Golgi apparatus. Furthermore, it is highly active against the erythrocytic stage of Plasmodium Vivax, Malariae and most strains of Falciparum. Hydroxychloroquine is now most often used as an anti-rheumatological agent in Systemic Lupus Erythematosus (SLE) and Rheumatoid arthritis [21].Hydroxychloroquine, apart from being less toxic than Chloroquine is also more soluble owing to the presence of its N-hydroxyethyl side chain instead of N-diethyl group which is present in Chloroquine [22].
Anti-viral property of Hydroxychloroquine
The spike protein of SARS-CoV-2 interacts strongly with the human ACE2 receptor [1]. The virus uses this receptor to enter the cells. Hydroxychloroquine is known to be a weak base that elevated the pH of intracellular organelles, as discussed above. It inhibits the entry of SARS-CoV-2 by modifying the glycosylation of the ACE 2 receptor and spike protein [23-24].Increased levels of Interleukin 6 and Tumor Necrosis Factor-alpha have well been documented in different viral infections like Hepatitis C virus, Hepatitis B virus, Influenza virus, Chikungunya virus and most importantly the Severe acute respiratory syndrome virus (SARS-CoV-2) [25-28]. Hydroxychloroquine has a regulatory effect on activated immune cells. It reduces the production of cytokines, Interleukin 1 and Interleukin 6, through macrophages by down regulating the expression of Toll-like receptors, inhibiting T and B cell receptors [22, 29, 30]. This pro-inflammatory status has provided the rationale for the use of Hydroxychloroquine as a potential treatment option in COVID-19.
Importantly, the lung is the major organ affected in COVID-19. Hydroxychloroquine has a wide distribution in the lung where the drug concentration reaches a hundred times more than that in blood. Due to this property, enough concentration can be achieved for its inhibitory effects on the lungs [41].
Treatment of COVID-19 with Hydroxychloroquine
The first study on the effect of Hydroxychloroquine on CIVID-19 was conducted by Philippe Guatret where patients were given the drug in a dose of 200mg thrice a day. There had been a rapid fall of the nasopharyngeal viral load. The study indicated that Hydroxychloroquine might be effective against COVID-19 [31]. However, it is reported to have several limitations; a small population with only 2 patients who received Hydroxychloroquine (6 of whom received Azithromycin), the observation period of 6 days was very short, no randomization was done [32]. The viral clearance was superior in patients receiving Hydroxychloroquine plus Azithromycin (100%) compared with Hydroxychloroquine monotherapy (57%) [33].
The second French study conducted by Guatret was relatively larger but it lacked a control group. These patients were given Hydroxychloroquine 200mg every 12 hours. The overall clinical outcome was similar to that of patients with COVID-19 who did not get any treatment [32, 34].In a trial of 30 patients carried out by Jun Chen and his colleagues, the efficacy of Hydroxychloroquine was compared to local standard care. No major difference was found in the nasopharyngeal viral carriage on the 7th day of the trial [35].
Hydroxychloroquine (200mg every 12 hours) in a randomized control trial of 62 patients was associated with a shorter recovery time in patients suffering from a milder form of the disease [36].
Interestingly, a physiologically based pharmacokinetic modeling study has recommended a treatment regimen of Hydroxychloroquine in COVID 19 in a loading dose of 400mg twice daily on day 1 followed by 200mg twice daily [41]. Few large scale clinical trials are planned and registered for evaluating the efficacy of Hydroxychloroquine in COVID-10; HYCOVID trial (NCT04325893) [37], PATCH trial (NCT04329923) that consists of 3 cohorts determining the role of the drug in COVID-19 positive patients quarantined at home, hospitalized and health care workers [38], ORCHID trial (NCT04332991)[39] (Table1a)
Old aged patients with multiple comorbidities are at a higher risk of acquiring the SARS-CoV-2 infection. In A case report of a 72-year old patient with a heart transplant who was receiving immunosuppressive therapy tested positive for the disease. He had interstitial pneumonia at the time of diagnosis. The patient was commenced on Hydroxychloroquine therapy with no further declination in his clinical status. After 12 days of hospitalization he tested negative for SARS-CoV-2 and was completely asymptomatic [40].
Yao et al tested the effect of Chloroquine and Hydroxychloroquine in vitro. Their study was divided into two groups; treatment and prophylaxis. They compared the half-maximal effective concentration, EC50, of these two drugs at different time intervals. In the treatment group, the EC50 values of Chloroquine were 23.9µM and 5.47µM at 24 and 48 hours; while those for Hydroxychloroquine were 6.14µM and 0.72µM at 24 and 48 hours, respectively. Based on these marked differences between the EC50 values, they concluded that Hydroxychloroquine is more effective in vitro than Chloroquine for the treatment of COVID-19 [41].
Safety profile of Hydroxychloroquine
Treatment with Hydroxychloroquine is generally well tolerated by patients and the adverse effects are usually dose and duration related. Common side effects include mild dermatological, gastrointestinal and neurological features. Less common adverse effects include retinopathy and cardiac arrhythmias (prolonged QT interval) [42]. With the usual dose (≤5mg/kg) retinopathy occurs in up to 3.5% of patients taking Hydroxychloroquine [43].
Although not frequent, a case of severe hepatotoxicity resulting from the use of Hydroxychloroquine has been reported in a patient with severe SARS-CoV-2 infection. After the commencement of the therapy, serum transaminase levels raised 10 times that of normal, which declined rapidly after the withdrawal of the drug [44]. Nevertheless, as proven by various studies, the overall toxicity and side effect profile of Hydroxychloroquine is quite less, making it a relatively safer drug to use. Jun et al reported adverse events in 4(26.7%0 patients who received 400mg of Hydroxychloroquine per day and in 3 (20%) patients in the control group [45]. In another study as reported by Chen at el, 2 patients experienced very mild reactions in the treatment arm after being treated with Hydroxychloroquine (400mg/day) for 5 days [36]. Guatret et al, reported mild side effects that included blurring of vision in 1.2%, diarrhea in 5% and vomiting in 5% of patients [31].
COVID-19 in patients with Rheumatic diseases
Hydroxychloroquine has been famous as a potential treatment option in different rheumatic diseases, mainly Rheumatoid arthritis and Systemic Lupus Erythematosus (SLE). Hence, the relationship between the occurrence of COVID-19 in patients with rheumatic diseases in an interesting topic, especially for the rheumatologists.
A case series conducted in Lombardy Italy, on patients with chronic rheumatic diseases (rheumatoid arthritis and Spondyloarthropathy) who were being treated with targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. Information was collected from 320 patients. Out of these, 4 were confirmed cases of COVID-19 diagnosed through nasopharyngeal swab, and 4 were highly suggestive of COVID-19 on clinical grounds. Overall, 5 patients were on previous treatment with Hydroxychloroquine. DMARDs, except Hydroxychloroquine, were withdrawn from all patients with symptoms of the illness. None of the patients developed respiratory complications or died except for 1 patient who required low flow oxygen for a few days. Nevertheless, in 3 of 8 symptomatic patients who were taking Hydroxychloroquine, it did not seem to the prevent occurrence of infection in these cases [46]. No definite conclusion can be drawn from such a small population of patients regarding the incidence of COVID-19 in patients with chronic rheumatic diseases taking Hydroxychloroquine, a high surveillance with a strict follow up is required. However, the preliminary experience shows that patients treated with DMARDs, mainly Hydroxychloroquine, do not seem to be at a high risk of respiratory or life-threatening complications from SARS-CoV-2 when compared to the general population.
Little evidence can also be taken by the fact that there is no case of SLE identified with COVID-19, as stated by Joob in a comment [47]. Even so, this might only be a matter of time researchers learn about SLE patients with COVID-19. Nonetheless, corroboration otherwise is also available. A 61-year old female who has been a known case of Rheumatoid arthritis for last the 3 years and achieved disease remission with Leflunomide and Hydroxychloroquine was positive for COVID-19. Her only initial symptoms were myalgia and fever for 4 days. Her symptoms worsened 3 days after her admission and she developed pneumonia. The patient later improved after discontinuation of her conventional DMARDs (except Hydroxychloroquine) and the addition of anti-viral agents [48].
Interestingly, a recently published paper explains the mechanism of epigenetic dysregulation that could not only put patients with SLE at an increased risk of COVID-19 but also cause a severe form of the disease, regardless of the immunosuppressive therapy these patients are taking. There are hypomethylation and overexpression of ACE 2 in patients with SLE, which encodes the receptor for SARS-CoV-2 spike protein. This potentiated the entry of the virus into the cells. Furthermore, viral infections induce oxidative stress that would exacerbate the DNA methylation defect, perpetuating the mechanism. Similar modifications to interferon regulated genes would also exacerbate the immune reaction to SARS-CoV-2 in such patients [49].
The preventive role of Hydroxychloroquine in patients with rheumatic diseases taking the drug chronically is a currently unresolved issue that needs an extensive and detailed evaluation.
Conclusion and recommendations
After analyzing the current literature and available studies, we concluded that the anti-viral properties of Hydroxychloroquine have demonstrated in vitro activity against SARS-CoV-2 with promising results. In our opinion, the use of this agent in treating SARS-CoV-2 infection is safe. Considering the potential efficacy, low priced, easy availability, and reduced risk of toxicity, we recommend the use of Hydroxychloroquine in patients with COVID-19. The results of the clinical trials reviewed here showed that Hydroxychloroquine is efficacious in the treatment and supportive care of COVID-19 patients. However, to obtain the highest grade of evidence results from large, multicenter, double-blinded studies are required
Conflicts of interests
None declared by any of the author
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
